What is OurPharma?
OurPharma operates as a sophisticated player in the pharmaceutical sector, specifically focusing on the production of high-quality compounded medications. By leveraging a state-of-the-art 503B outsourcing facility, the company addresses the persistent demand for sterile injectables, intravenous fluids, and medication cassettes. Their operational model is anchored in rigorous FDA-regulated analytics testing, which serves as a primary differentiator in a market where quality assurance and supply chain reliability are paramount. By serving healthcare organizations directly, OurPharma bridges the gap between complex pharmaceutical development and the immediate, high-stakes needs of clinical providers and their patients.
How much funding has OurPharma raised?
OurPharma has raised a total of $709K across 3 funding rounds:
Debt
$150K
Debt
$309K
Stock/Share Issuance
$250K
Debt (2020): $150K with participation from PPP
Debt (2021): $309K led by PPP
Stock/Share Issuance (2025): $250K, investors not publicly disclosed
Key Investors in OurPharma
Undisclosed Investor
An institutional partner providing strategic capital to support the scaling of high-compliance pharmaceutical manufacturing operations.
PPP
Public-Private Partnership
What's next for OurPharma?
With this recent strategic investment, OurPharma is well-positioned to accelerate its market penetration and enhance its manufacturing throughput. The company is expected to prioritize the expansion of its sterile production lines and further integrate advanced analytics into its quality control protocols. As the healthcare industry continues to grapple with supply chain volatility, OurPharma's commitment to transparency and regulatory compliance provides a stable foundation for long-term growth. Future initiatives will likely focus on scaling capacity to meet the evolving requirements of large-scale healthcare networks, ensuring that the firm remains a preferred partner for essential pharmaceutical solutions.
See full OurPharma company page
